Like_老虎社区_美港股上老虎

Desmondsim
2021-12-01

Pfizer Has Best Month in 30 Years After Leading Vaccine Race

Pfizer Inc. closed out November trading with its best monthly advance in 30 years, as renewed virus

Pfizer Has Best Month in 30 Years After Leading Vaccine Race

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":609414330,"tweetId":"609414330","gmtCreate":1638317365308,"gmtModify":1638317365398,"author":{"id":3581894830339885,"idStr":"3581894830339885","authorId":3581894830339885,"authorIdStr":"3581894830339885","name":"Desmondsim","avatar":"https://static.tigerbbs.com/9484cf4599b477a3985c44fe04da87b3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":16,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609414330","repostId":1135257969,"repostType":4,"repost":{"id":"1135257969","kind":"news","pubTimestamp":1638316721,"share":"https://www.laohu8.com/m/news/1135257969?lang=&edition=full","pubTime":"2021-12-01 07:58","market":"us","language":"en","title":"Pfizer Has Best Month in 30 Years After Leading Vaccine Race","url":"https://stock-news.laohu8.com/highlight/detail?id=1135257969","media":"Bloomberg","summary":"Pfizer Inc. closed out November trading with its best monthly advance in 30 years, as renewed virus ","content":"<p>Pfizer Inc. closed out November trading with its best monthly advance in 30 years, as renewed virus fears revive the market’s focus on vaccine makers.</p>\n<p>The stock rose 2.5% to $53.73 in New York trading on Tuesday, ending the month with a 23% gain -- the most since 1991. Pfizer is up about 46% so far this year, with its dividend boosting the total return to more than 50%.</p>\n<p>The last time Pfizer was this hot, George H.W. Bush was the U.S. president, 10-year Treasuries yielded more than 7.8%, AIDS was the virus striking fear in the public and Pfizer’s promising new drugs were Procardia to ease angina and Diflucan to combat fungal infections.</p>\n<p>The company behind one of the world’s best-selling vaccines was spurred to new heights this week as investors contemplated an ongoing need for shots and boosters to counter the new omicron Covid-19 variant. Pfizer is racing to test its current vaccine against omicron and, if needed, could develop a new shot within 100 days, according to Chief Executive Officer Albert Bourla.</p>\n<p>The pharmaceutical company and its partner BioNTech SE were the first to secure a U.S. authorization for a Covid-19 vaccine. Pfizer is also awaiting a regulatory update on a pill to treat early cases of the disease. So far the oral antiviral medicine appears to work better than a similar therapy from Merck &amp; Co.</p>\n<p>Retail traders were net buyers of Pfizer on Tuesday, according to Fidelity data. The renewed enthusiasm for Pfizer comes after the day-trading crowd sold off their vaccine holdings in October.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Has Best Month in 30 Years After Leading Vaccine Race</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Has Best Month in 30 Years After Leading Vaccine Race\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 07:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pfizer-set-best-month-30-153850519.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. closed out November trading with its best monthly advance in 30 years, as renewed virus fears revive the market’s focus on vaccine makers.\nThe stock rose 2.5% to $53.73 in New York trading...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizer-set-best-month-30-153850519.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/pfizer-set-best-month-30-153850519.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135257969","content_text":"Pfizer Inc. closed out November trading with its best monthly advance in 30 years, as renewed virus fears revive the market’s focus on vaccine makers.\nThe stock rose 2.5% to $53.73 in New York trading on Tuesday, ending the month with a 23% gain -- the most since 1991. Pfizer is up about 46% so far this year, with its dividend boosting the total return to more than 50%.\nThe last time Pfizer was this hot, George H.W. Bush was the U.S. president, 10-year Treasuries yielded more than 7.8%, AIDS was the virus striking fear in the public and Pfizer’s promising new drugs were Procardia to ease angina and Diflucan to combat fungal infections.\nThe company behind one of the world’s best-selling vaccines was spurred to new heights this week as investors contemplated an ongoing need for shots and boosters to counter the new omicron Covid-19 variant. Pfizer is racing to test its current vaccine against omicron and, if needed, could develop a new shot within 100 days, according to Chief Executive Officer Albert Bourla.\nThe pharmaceutical company and its partner BioNTech SE were the first to secure a U.S. authorization for a Covid-19 vaccine. Pfizer is also awaiting a regulatory update on a pill to treat early cases of the disease. So far the oral antiviral medicine appears to work better than a similar therapy from Merck & Co.\nRetail traders were net buyers of Pfizer on Tuesday, according to Fidelity data. The renewed enthusiasm for Pfizer comes after the day-trading crowd sold off their vaccine holdings in October.","news_type":1},"isVote":1,"tweetType":1,"viewCount":942,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Pfizer Has Best Month in 30 Years After Leading Vaccine Race

评论（1）

热议股票